BURDEN, RISK FACTORS AND PREVENTION OF RESPIRATORY INFECTIONS AND INFECTIOUS DISEASES IN CHILDREN
Associate Professor Hannah Moore OAM
Program Head, Infection and Vaccines,
The Kids Research Institute Australia &
Associate Professor at the School of Population Health, Curtin University
Western Australia
RESEARCHER PROFILE (Filmed in Perth, Western Australia | December 2024)
A/Prof Hannah Moore OAM is an infectious disease epidemiologist; Co-Head of the Infectious Disease Epidemiology team within the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia and Associate Professor at the School of Population Health, Curtin University in Western Australia.
Her passion for research involves using population-based data to investigate how to recognise, prevent and reduce serious respiratory and other infectious diseases in children through estimating burden of disease and evaluating the effectiveness of vaccination programs. She has developed expertise in the epidemiology of Respiratory Syncytial Virus (RSV) in young children, where her research was pivotal in WA Governments’ decision to establish the first and most comprehensive RSV infant immunisation program in the nation. Raising awareness of RSV, understanding community burden and evaluating the impact of prevention measures is now a major focus of her research program. She has previously contributed to state and national influenza vaccination policy.
In 2020 A/Prof Moore joined the Strep A Vaccine Global Consortium (SAVAC) to increase knowledge and awareness of the global burden of Group A Streptococcal diseases. She now holds an activity lead position in the US$11M-funded SAVAC 2.0.
A/Prof Moore has been awarded more than $19M in competitive research grants, co-authored more than 140 papers, was TEDxPerth 2018 speaker, recipient of a WA Young Tall Poppy Award (2013) and the WA Premiers Science Early Career Scientist Award (2015). In 2024, she was honoured with a Medal of the Order of Australia for her service to epidemiology as a researcher.
Editor’s note: At the time of recording in September 2024, A/Prof Hannah Moore makes reference to needing a national RSV immunisation program. Efforts by her and others in campaigning were successful and in November 2024 the Australian National Immunisation Program was updated to include RSV from 2025. https://www.health.gov.au/news/national-immunisation-program-update-rsv-vaccine#:~:text=The%20inclusion%20of%20the%20RSV,announced%20as%20soon%20as%20possible.
https://orcid.org/0000-0003-4920-9991
-
Anne O’Neill
STATE GOVERNMENT SUPPORTING MEDICAL RESEARCH
@ NSW HEALTH, NEW SOUTH WALES AUSTRALIA -
Joanne Chio
ICON CANCER CENTRE – SINGAPORE
SINGAPORE -
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
